You just read:

Isis Pharmaceuticals Initiates SHINE Study to Provide ISIS-SMN Rx for Patients With SMA Who Have Completed the Phase 3 ENDEAR and CHERISH Studies

News provided by

Isis Pharmaceuticals, Inc.

Oct 15, 2015, 07:33 ET